Clinical Trial: A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.

U.S., June 16 -- ClinicalTrials.gov registry received information related to the study (NCT07647224) titled 'A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.' on May 24.

Brief Summary: This is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and immunogenicity characteristics of GR2301 injection in healthy adult subjects in China. The Multiple doses will be gradually escalated.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Multiple Dose Healthy Adult Participants

Intervention: DRUG: GR2301 injection

IL15 monoclonal antibody

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Genrix (Shangh...